mation Disclosure Statement (IDS) Filed

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlies it contains a suid OMB control/pumber. Do description: Information Disclosure Statement (IDS) Filed

\	
NFORMATION DISCLOSURI	=
STATEMENT BY APPLICANT	
Not for submission under 27 CER 1 99	

Application Number		10802000	
Filing Date		2004-03-16	
First Named Inventor	Thom	s Nadackal Thomas	
Art Unit		1629	
Examiner Name	Phylli	s G. Spivack	
			_/

				Attorn	ey Doc	ket Number	1996.01			
					U.S.I	PATENTS		/-	Remove	_
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D)ate	Name of Pate of cited Docu	entee or Applicant ment	Relev	es,Columns,Lines wher vant Passages or Rele res Appear	
	1									
If you wis	h to ad	d additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	_
			U.S.P	ATENT	APPLI	CATION PUBL	ICATIONS		Remove	
Examiner Initial*	Cite N	Publication Number	Kind Code ¹	Publica Date	ation	Name of Pate of cited Docu	ntee or Applicant ment	Relev	es,Columns,Lines wher vant Passages or Rele res Appear	
	1				/					
If you wis	h to ad	ld additional U.S. Publ	ished Ap	lication	citation	n information p	lease click the Ad	d butto	on. Add	
				FOREIG	3N PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patente Applicant of oteo Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	T5
	1									
If you wis	h to ad	d additional Foreign P	atent Do	cument	citation	information ple	ease click the Add	buttor	n Add	
			МОМ	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner	Cite	Include name of the a								T5

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s

publisher, city and/or country where published.

Initials*

Attorney Docket Number

1996.01

/P.S./	1	Wikip	eedia definition of Aspirin. http://en.wikipedia.org/wiki/Aspirin, access	ssed March 6, 2012.		
/P.S./	2		tUCCI, S. Prevention of Nonsteroidal Anti-Inflammatory Drug-Indux N Am, 38:315-332, 2009.	ced Ulcer: Looking to the	ne Future. Gastroenterol	
/P.S./	/P.S./ 3 Sigma-Aldrich product Information for Propargylamine. http://sigmaaldrich.com/catalog/ProductDetail.do? D7=08N5=SEARCH_CONCAT, accessed March 6, 2012.					
/P.S./ 4 Wikipedia definition of Selegiline. http://en.wikipedia.org/wiki/Selegiline, accessed March 6, 2012.						
If you wis	h to a	dd add	ditional non-patent literature document citation information p	lease click the Add b	outton Add	
			EXAMINER SIGNATURE			
Examiner	Signa	ature	/Phyllis Spivack/	Date Considered	11/09/2012	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

Receipt date: 03/08/2012 Application Number 10802000 2004-03-16 Filing Date INFORMATION DISCLOSURE First Named Inventor Thoms Nadackal Thomas STATEMENT BY APPLICANT Art Unit 1629 (Not for submission under 37 CFR 1.99) Examiner Name Phyllis G. Spivack Attorney Docket Number 1996 01 CERTIFICATION STATEMENT Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s): That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1). OR That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification

See attached certification statement.

statement. See 37 CFR 1.97(e)(2).

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

A certification statement is not submitted herewith.

SIGNATURE

after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/robert varkonyı/	Date (YYYY-MM-DD)	2012-03-08
Name/Print	Robert Varkonyi	Registration Number	63885

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22314-1450.

Receipt date: 03/08/2012

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) tuning of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.